Aelex: The indication of first-line treatment with vemurafenib is included in the breakthrough therapy drug program notification.

Ailis announcement: The core product, gefitinib fumarate tablets, has recently been included in the National Medical Products Administration Drug Evaluation Center's list of proposed breakthrough therapies, with the proposed indication being first-line treatment for adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor PACC mutation. The public notice period is from December 25, 2025 to January 4, 2026.